TT-00434 is under clinical development by TransThera Sciences (Nanjing) and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TT-00434’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TT-00434 overview

TT-00434 is under development for the treatment of advanced solid tumors, bladder cancer, cholangiocarcinoma and gastrointestinal tumor and gastric caner. It acts by targeting fibroblast growth factor receptor 1, 2, 3 (FGFR1, FGFR2 and FGFR3).

TransThera Sciences (Nanjing) overview

TransThera Sciences (Nanjing) (TransThera Sciences) is a biotechnology company, dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via the internal research platform and open innovation. The company develops and commercializes small molecule therapeutic agents for cancer, cardiovascular and inflammatory diseases. It focuses on the discovery and development of highly differentiated small-molecule new drugs and serving the medical needs of patients worldwide. Its oncology product portfolio includes TT-00420, TT-00434, TT-01488, TT-009373, and TT-ROMI. Its non-oncology products are TT-00920, TT-01688, TT-01025 and TT-RIAN. TransThera Sciences is headquartered in Nanjing, Jiangsu, China.

For a complete picture of TT-00434’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.